CLAIMS

1. Saponin derivative based on a saponin comprising a triterpene aglycone core structure and at least one of a first saccharide chain and a second saccharide chain linked to the aglycone core structure, wherein the aglycone core structure is quillaic acid or gypsogenin; wherein the saponin on which the saponin derivative is based is not a *Quillaja saponaria* (QS) saponin, and is not a saponin of Quil-A;

and wherein:

i. the saponin derivative comprises an aglycone core structure comprising an aldehyde group which has been derivatised;
and optionally:

ii. the saponin derivative comprises the first saccharide chain wherein the first saccharide chain comprises a carboxyl group, preferably a carboxyl group of a glucuronic acid moiety, which has been derivatised; or


iii. the saponin derivative comprises the second saccharide chain wherein the second saccharide chain comprises at least one acetoxy (Me(CO)O-) group which has been derivatised; or



iv. the saponin derivative comprises combination of derivatisations i., and ii. or i. and iii.;

wherein the first saccharide chain and the second saccharide chain are independently selected from a monosaccharide, a linear oligosaccharide and a branched oligosaccharide;

wherein the aldehyde group at position C23 of the quillaic acid or gypsogenin has been derivatised by hydrazone formation with hydrazides, imine formation with amines or chemoselective reversible oxime formation with hydroxylamines;

with the proviso that the saponin derivative is not any one of the following saponin derivatives having formula (I), (II) and (V):

(I)	 SO1861-Ald-EMCH

(II)	 SO1861-azide
(V)	 SO1861-Ald-EMCH-mercaptoethanol

.


2. Saponin derivative according to claim 1, wherein the saponin is a naturally occuring saponin.



3. Saponin derivative according to any one of the claims 1-2, wherein the saponin derivative is a derivative of a saponin selected from the group of saponins consisting of: NP-017777, NP-017778, NP-017774, NP-018110, NP-017772, NP-018109, NP-017888, NP-017889, NP-018108, SA1641, AE X55, NP-017674, NP-017810, AG1, NP-003881, NP-017676, NP-017677, NP-017706, NP-017705, NP-017773, NP-017775, SA1657, AG2, GE1741, SO1542, SO1584, SO1658, SO1674, SO1832, SO1904, SO1862, stereoisomers thereof and combinations thereof, preferably the




saponin derivative is selected from the group consisting of a SO1832 derivative, a SA1641 derivative and a GE1741 derivative.





4. Saponin derivative according to any one of the claims 1-3, wherein the saponin derivative is not based on any of QS-7, QS1861, QS-7 api, QS1862, QS-17, QS-18, QS-21, QS-21 A-apio, QS-21 A-xylo, QS-21 B-apio, QS-21 B-xylo, and Quil-A.

5. Saponin derivative according to any one of claims 1-4, with the proviso that the saponin derivative is not any one of the following saponin derivatives having formula (X)-(XII), (XVIII)-(XXI), (XXXVII)-(XXXIX):

(X)	 wherein Z^1 is hydrogen or glucose; sperminine aldehydic desacylated quillaja saponin

(XI)	 wherein Z^1 is hydrogen or glucose; 3-dimethylamino-1-propylamine-dodecylamine desacylated quillaja saponin
(XII)	 wherein Z^1 is hydrogen or glucose; Dodecyl amide saponin-spermine aldehydic deacylated quillaja saponin

(XVIII)	 wherein Z^2 is either apiose or xylose; Glycine aldehydic QA-21
(XIX)	 wherein Z^2 is either apiose or xylose; Ethylene diamine aldehydic QA-21
(XX)	 wherein Z^2 is either apiose or xylose; Ethyl amine aldehydic QA-21

(XXI)	 wherein Z^2 is either apiose or xylose; Alcohol QA-21
(XXXVII)	 Bn = benzyl and TES = triethylsilyl; protected aminoacyl caullophylogenin saponin
(XXXVIII)	 Aminoacyl caullophylogenin saponin
(XXXIX)	 SQS-1-11-5-18

6. Saponin derivative according to any one of claims 1-5, wherein the saponin derivative is a monodesmosidic triterpene glycoside or a bidesmosidic triterpene glycoside, more preferably a bidesmosidic triterpene glycoside.

7. Saponin derivative according to any one of claims 1-6, wherein the saponin derivative comprises the first saccharide chain wherein the first saccharide chain comprises a carboxyl group, preferably a carboxyl group of a glucuronic acid moiety, which has been derivatised.

8. Saponin derivative according to any one of claims 1-7, wherein the saponin derivative comprises the second saccharide chain wherein the second saccharide chain comprises at least one acetoxy (Me(CO)O-) group which has been derivatised,

9. Saponin derivative according to any one of the claims 1-8, wherein the first saccharide chain, when present, is linked to the C_3 atom or the C_{28} atom of the aglycone core structure, preferably to the C_3 atom, and/or wherein the second saccharide chain, when present, is linked to the C_{28} atom of the aglycone core structure.

10. Saponin derivative according to any one of the claims 1-9, wherein the first saccharide chain, if present, is selected from:

GlcA-,
Glc-,
Gal-,
Rha-(1→2)-Ara-,
Gal-(1→2)-[Xyl-(1→3)]-GlcA-,
Glc-(1→2)-[Glc-(1→4)]-GlcA-,
Glc-(1→2)-Ara-(1→3)-[Gal-(1→2)]-GlcA-,
Xyl-(1→2)-Ara-(1→3)-[Gal-(1→2)]-GlcA-,
Glc-(1→3)-Gal-(1→2)-[Xyl-(1→3)]-Glc-(1→4)-Gal-,
Rha-(1→2)-Gal-(1→3)-[Glc-(1→2)]-GlcA-,
Ara-(1→4)-Rha-(1→2)-Glc-(1→2)-Rha-(1→2)-GlcA-,
Ara-(1→4)-Fuc-(1→2)-Glc-(1→2)-Rha-(1→2)-GlcA-,
Ara-(1→4)-Rha-(1→2)-Gal-(1→2)-Rha-(1→2)-GlcA-,
Ara-(1→4)-Fuc-(1→2)-Gal-(1→2)-Rha-(1→2)-GlcA-,
Ara-(1→4)-Rha-(1→2)-Glc-(1→2)-Fuc-(1→2)-GlcA-,
Ara-(1→4)-Fuc-(1→2)-Glc-(1→2)-Fuc-(1→2)-GlcA-,
Ara-(1→4)-Rha-(1→2)-Gal-(1→2)-Fuc-(1→2)-GlcA-,
Ara-(1→4)-Fuc-(1→2)-Gal-(1→2)-Fuc-(1→2)-GlcA-,
Xyl-(1→4)-Rha-(1→2)-Glc-(1→2)-Rha-(1→2)-GlcA-,
Xyl-(1→4)-Fuc-(1→2)-Glc-(1→2)-Rha-(1→2)-GlcA-,
Xyl-(1→4)-Rha-(1→2)-Gal-(1→2)-Rha-(1→2)-GlcA-,


Xyl-(1→4)-Fuc-(1→2)-Gal-(1→2)-Rha-(1→2)-GlcA-,
Xyl-(1→4)-Rha-(1→2)-Glc-(1→2)-Fuc-(1→2)-GlcA-,
Xyl-(1→4)-Fuc-(1→2)-Glc-(1→2)-Fuc-(1→2)-GlcA-,
Xyl-(1→4)-Rha-(1→2)-Gal-(1→2)-Fuc-(1→2)-GlcA-,
Xyl-(1→4)-Fuc-(1→2)-Gal-(1→2)-Fuc-(1→2)-GlcA-, and
derivatives thereof,
and/or wherein the second saccharide chain, if present, is selected from:
Glc-,
Gal-,
Rha-(1→2)-[Xyl-(1→4)]-Rha-,
Rha-(1→2)-[Ara-(1→3)-Xyl-(1→4)]-Rha-,
Ara-,
Xyl-,
Xyl-(1→4)-Rha-(1→2)-[R1-(→4)]-Fuc- wherein R1 is 4E-Methoxycinnamic acid,
Xyl-(1→4)-Rha-(1→2)-[R2-(→4)]-Fuc- wherein R2 is 4Z-Methoxycinnamic acid,
Xyl-(1→4)-[Gal-(1→3)]-Rha-(1→2)-4-OAc-Fuc-,
Xyl-(1→4)-[Glc-(1→3)]-Rha-(1→2)-3,4-di-OAc-Fuc-,
Xyl-(1→4)-[Glc-(1→3)]-Rha-(1→2)-[R3-(→4)]-3-OAc-Fuc- wherein R3 is 4E-Methoxycinnamic acid,
Glc-(1→3)-Xyl-(1→4)-[Glc-(1→3)]-Rha-(1→2)-4-OAc-Fuc-,
Glc-(1→3)-Xyl-(1→4)-Rha-(1→2)-4-OAc-Fuc-,
(Ara- or Xyl-)(1→3)-(Ara- or Xyl-)(1→4)-(Rha- or Fuc-)(1→2)-[4-OAc-(Rha- or Fuc-)(1→4)]-(Rha- or Fuc-),
Xyl-(1→3)-Xyl-(1→4)-Rha-(1→2)-[Qui-(1→4)]-Fuc-,
Api-(1→3)-Xyl-(1→4)-[Glc-(1→3)]-Rha-(1→2)-Fuc-,
Xyl-(1→4)-[Gal-(1→3)]-Rha-(1→2)-Fuc-,
Xyl-(1→4)-[Glc-(1→3)]-Rha-(1→2)-Fuc-,
Ara/Xyl-(1→4)-Rha/Fuc-(1→4)-[Glc/Gal-(1→2)]-Fuc-,
Api-(1→3)-Xyl-(1→4)-[Glc-(1→3)]-Rha-(1→2)-[R4-(→4)]-Fuc- wherein R4 is 5-O-[5-O-Ara/Api-3,5-dihydroxy-6-methyl-octanoyl]-3,5-dihydroxy-6-methyl-octanoic acid),
Api-(1→3)-Xyl-(1→4)-Rha-(1→2)-[R5-(→4)]-Fuc- wherein R5 is 5-O-[5-O-Ara/Api-3,5-dihydroxy-6-methyl-octanoyl]-3,5-dihydroxy-6-methyl-octanoic acid),
Api-(1→3)-Xyl-(1→4)-Rha-(1→2)-[Rha-(1→3)]-4-OAc-Fuc-,
Api-(1→3)-Xyl-(1→4)-[Glc-(1→3)]-Rha-(1→2)-[Rha-(1→3)]-4-OAc-Fuc-,
6-OAc-Glc-(1→3)-Xyl-(1→4)-Rha-(1→2)-[3-OAc-Rha-(1→3)]-Fuc-,
Glc-(1→3)-Xyl-(1→4)-Rha-(1→2)-[3-OAc--Rha-(1→3)]-Fuc-,
Xyl-(1→3)-Xyl-(1→4)-Rha-(1→2)-[Qui-(1→4)]-Fuc-,
Glc-(1→3)-[Xyl-(1→4)]-Rha-(1→2)-[Qui-(1→4)]-Fuc-,
Glc-(1→3)-Xyl-(1→4)-Rha-(1→2)-[Xyl-(1→3)-4-OAc-Qui-(1→4)]-Fuc-,
Xyl-(1→3)-Xyl-(1→4)-Rha-(1→2)-[3,4-di-OAc-Qui-(1→4)]-Fuc-,
Glc-(1→3)-[Xyl-(1→4)]-Rha-(1→2)-Fuc-,

6-OAc-Glc-(1→3)-[Xyl-(1→4)]-Rha-(1→2)-Fuc-,
Glc-(1→3)-[Xyl-(1→3)-Xyl-(1→4)]-Rha-(1→2)-Fuc-,
Xyl-(1→3)-Xyl-(1→4)-Rha-(1→2)-[Xyl-(1→3)-4-OAc-Qui-(1→4)]-Fuc-,
Api/Xyl-(1→3)-Xyl-(1→4)-[Glc-(1→3)]-Rha-(1→2)-[Rha-(1→3)]-4OAc-Fuc-,
Api-(1→3)-Xyl-(1→4)-[Glc-(1→3)]-Rha-(1→2)-[Rha-(1→3)]-4OAc-Fuc-,
Api/Xyl-(1→3)-Xyl-(1→4)-[Glc-(1→3)]-Rha-(1→2)-[R6-(→4)]-Fuc- wherein R6 is 5-O-[5-O-Rha-(1→2)-Ara/Api-3,5-dihydroxy-6-methyl-octanoyl]-3,5-dihydroxy-6-methyl-octanoic acid),
Api/Xyl-(1→3)-Xyl-(1→4)-[Glc-(1→3)]-Rha-(1→2)-[R7-(→4)]-Fuc- wherein R7 is 5-O-[5-O-Ara/Api-3,5-dihydroxy-6-methyl-octanoyl]-3,5-dihydroxy-6-methyl-octanoic acid),
Api/Xyl-(1→3)-Xyl-(1→4)-[Glc-(1→3)]-Rha-(1→2)-[R8-(→4)]-Fuc- wherein R8 is 5-O-[5-O-Ara/Api-3,5-dihydroxy-6-methyl-octanoyl]-3,5-dihydroxy-6-methyl-octanoic acid),
Api-(1→3)-Xyl-(1→4)-Rha-(1→2)-[R9-(→4)]-Fuc- wherein R9 is 5-O-[5-O-Ara/Api-3,5-dihydroxy-6-methyl-octanoyl]-3,5-dihydroxy-6-methyl-octanoic acid),
Xyl-(1→3)-Xyl-(1→4)-Rha-(1→2)-[R10-(→4)]-Fuc- wherein R10 is 5-O-[5-O-Ara/Api-3,5-dihydroxy-6-methyl-octanoyl]-3,5-dihydroxy-6-methyl-octanoic acid),
Api-(1→3)-Xyl-(1→4)-Rha-(1→2)-[R11-(→3)]-Fuc- wherein R11 is 5-O-[5-O-Ara/Api-3,5-dihydroxy-6-methyl-octanoyl]-3,5-dihydroxy-6-methyl-octanoic acid),
Xyl-(1→3)-Xyl-(1→4)-Rha-(1→2)-[R12-(→3)]-Fuc- wherein R12 is 5-O-[5-O-Ara/Api-3,5-dihydroxy-6-methyl-octanoyl]-3,5-dihydroxy-6-methyl-octanoic acid)
Glc-(1→3)-[Glc-(1→6)]-Gal-, and
derivatives thereof.

11. Saponin derivative according to any one of the claims 1-10, wherein the saponin derivative comprises the first saccharide chain and comprises the second saccharide chain, wherein the first saccharide chain comprises more than one saccharide moiety and the second saccharide chain comprises more than one saccharide moiety, wherein one or two of:

i. the first saccharide chain comprises a carboxyl group of a glucuronic acid moiety which has been derivatised, and
ii. the second saccharide chain comprises at least one acetoxy (Me(CO)O-) group which has been derivatised.

12. Saponin derivative according to any one of the claims 1-11, wherein the saponin derivative is represented by Molecule 1:



(Molecule 1)

wherein

the first saccharide chain A_1 represents hydrogen, a monosaccharide or a linear or branched oligosaccharide, preferably A_1 represents a saccharide chain as defined in claim 10, more preferably A_1 represents a saccharide chain as defined in claim 10 and A_1 comprises or consists of a glucuronic acid moiety;

the second saccharide chain A_2 represents hydrogen, a monosaccharide or a linear or branched oligosaccharide, preferably A_2 represents a saccharide chain as defined in claim 10, more preferably A_2 represents a saccharide chain as defined in claim 10 and A_2 comprises at least one acetoxy (Me(CO)O-) group, such as one, two, three or four acetoxy groups, wherein at least one of A_1 and A_2 is not hydrogen, preferably both A_1 and A_2 are an oligosaccharide chain;

and R is hydrogen in gypsogenin or hydroxyl in quillaic acid;

wherein the saponin derivative corresponds to the saponin represented by Molecule 1 wherein at least one of the following derivatisations is present:

i. the carboxyl group of a glucuronic acid moiety of A_1, when A_1 represents a saccharide chain as defined in claim 10 and A_1 comprises or consists of a glucuronic acid moiety, has been derivatised; and

ii. one or more, preferably all, of acetoxy group(s) of one saccharide moiety or of two or more saccharide moieties of A_2, when A_2 represents a saccharide chain as defined in claim 10 and A_2 comprises at least one acetoxy group, has/have been derivatised.

13. Saponin derivative according to claim 12, wherein A_1 represents a saccharide chain as defined in claim 10 and comprises or consists of a glucuronic acid moiety and wherein the carboxyl group of a glucuronic acid moiety of A_1 has been derivatised and/or wherein A_2 represents a saccharide chain as defined in claim 10 and A_2 of the saponin comprises at least one acetoxy group and wherein said at least one acetoxy group of A_2 has been derivatised in the saponin derivative.

14. Saponin derivative according to claim 12 or 13, wherein the saponin represented by Molecule 1 is a bidesmosidic triterpene saponin.

15. Saponin derivative according to any one of the claims 12-14, wherein the saponin derivative corresponds to the saponin represented by Molecule 1 wherein the following derivatisation is present:

the aldehyde group at position C_{23} of the quillaic acid or gypsogenin has been derivatised by either;

- transformation into a hydrazone bond through reaction with N-ε-maleimidocaproic acid hydrazide (EMCH), therewith providing a saponin-Ald-EMCH, wherein the maleimide group of the EMCH is optionally derivatised by formation of a thioether bond with mercaptoethanol; or
- transformation into a hydrazone bond through reaction with N-[ß-maleimidopropionic acid] hydrazide (BMPH) wherein the maleimide group of the BMPH is optionally derivatised by formation of a thioether bond with mercaptoethanol; or
- transformation into a hydrazone bond through reaction with N-[κ-maleimidoundecanoic acid] hydrazide (KMUH) wherein the maleimide group of the KMUH is optionally derivatised by formation of a thioether bond with mercaptoethanol;

and preferably at least one or two of the following derivatisations is present,

i. the carboxyl group of a glucuronic acid moiety of A_1, when A_1 represents a saccharide chain as defined in claim 10 and A_1 comprises or consists of a glucuronic acid moiety, has been derivatised by transformation into an amide bond through reaction with 2-amino-2-methyl-1,3-propanediol (AMPD) or *N*-(2-aminoethyl)maleimide (AEM), therewith providing a saponin-Glu-AMPD, or a saponin-Glu-AEM; and

ii. one or more, optionally all, of acetoxy group(s) of one saccharide moiety or of two or more saccharide moieties of A_2, when A_2 represents a saccharide chain as defined in claim 10 and A_2 comprises at least one acetoxy group, has/have been derivatised by transformation into a hydroxyl group (HO-) by deacetylation.

16. Saponin derivative according to any one of the claims 12-15, wherein A_1 is Gal-(1→2)-[Xyl-(1→3)]-GlcA and/or A_2 is Glc-(1→3)-Xyl-(1→4)-Rha-(1→2)-[Xyl-(1→3)-4-OAc-Qui-(1→4)]-Fuc, preferably the saponin represented by Molecule 1 is 3-O-beta-D-galactopyranosyl-(1→2)-[beta-D-xylopyranosyl-(1→3)]-beta-D-glucuronopyranosyl quillaic acid 28-O-beta-D-glucopyranosyl-(1→3)-beta-D-xylopyranosyl-(1→4)- alpha-L-rhamnopyranosyl-(1→2)-[beta-D-xylopyranosyl-(1→3)-4OAc-beta-D-quinovopyranosyl-(1→4)]-beta-D-fucopyranoside, more preferably SO1832, GE1741, SA1641.

17. Saponin derivative of any one of the claims 1-16, wherein the saponin derivative is selected from the group consisting of derivatives of: SA1657, GE1741, SA1641, Saponinum album, Gyp1, gypsoside A, AG1, AG2, SO1542, SO1584, SO1658, SO1674, SO1832, SO1862, SO1904, stereoisomers thereof and combinations thereof, preferably the saponin derivative is selected from the group consisting of a a GE1741 derivative, a SA1641 derivative, and a combination thereof.

18. Saponin derivative according to any one of the claims 1-17, wherein:

i. the saponin derivative comprises an aglycone core structure wherein the aglycone core structure comprises an aldehyde group which has been derivatised by either:

- transformation into a hydrazone bond through reaction with N-ε-maleimidocaproic acid hydrazide (EMCH) wherein the maleimide group of the EMCH is optionally derivatised by formation of a thioether bond with mercaptoethanol; or
- transformation into a hydrazone bond through reaction with N-[ß-maleimidopropionic acid] hydrazide (BMPH) wherein the maleimide group of the BMPH is optionally derivatised by formation of a thioether bond with mercaptoethanol; or
- transformation into a hydrazone bond through reaction with N-[κ-maleimidoundecanoic acid] hydrazide (KMUH) wherein the maleimide group of the KMUH is optionally derivatised by formation of a thioether bond with mercaptoethanol;

and optionally:

ii. the first saccharide chain comprises a carboxyl group, preferably a carboxyl group of a glucuronic acid moiety, which has been derivatised by transformation into an amide bond through reaction with 2-amino-2-methyl-1,3-propanediol (AMPD) or *N*-(2-aminoethyl)maleimide (AEM); or

iii. the second saccharide chain comprises an acetoxy group (Me(CO)O-) which has been derivatised by transformation into a hydroxyl group (HO-) by deacetylation; or

iv. the saponin derivative in i. optionally comprises any combination of one or two derivatisations ii. and iii.,;

preferably, wherein the aglycone core structure of the saponin derivative comprises said aldehyde group which has been derivatised by transformation into said hydrazone bond through reaction with EMCH wherein the maleimide group of the EMCH is optionally derivatised by formation of a thioether bond with mercaptoethanol.

19. First pharmaceutical composition comprising the saponin derivative according to any one of the claims 1-18 and optionally a pharmaceutically acceptable excipient and/or diluent.

20. Pharmaceutical combination comprising:

- the first pharmaceutical composition of claim 19; and
- a second pharmaceutical composition comprising any one or more of an antibody-oligonucleotide conjugate or a receptor-ligand – oligonucleotide conjugate, and optionally comprising a pharmaceutically acceptable excipient and/or diluent.

21. Third pharmaceutical composition comprising the saponin derivative of any one of the claims 1-18 and further comprising any one or more of: an antibody-nucleic acid conjugate or a receptor-ligand – nucleic acid conjugate, and optionally comprising a pharmaceutically acceptable excipient and/or diluent.

22. Pharmaceutical combination of claim 20 or the third pharmaceutical composition of claim 21, wherein the second pharmaceutical composition or the third pharmaceutical composition comprises any one or more of an antibody-oligonucleotide conjugate or a receptor-ligand – oligonucleotide conjugate, wherein the oligonucleotide is for example an siRNA or a BNA, for example for gene silencing of apolipoprotein B or HSP27.

23. Pharmaceutical combination of claim 20 or claim 22 or the third pharmaceutical composition of claim 21 or 22, wherein the saponin derivative is a saponin derivative according to claim 17.

24. First pharmaceutical composition of claim 19, pharmaceutical combination of any one of the claims 20 or 22-23 or the third pharmaceutical composition of any one of the claims 21-23, for use as endosomal escape enhancer for and in combination with an antibody-oligonucleotide conjugate or a receptor-ligand – oligonucleotide conjugate.

25. First pharmaceutical composition of claim 19, pharmaceutical combination of any one of the claims 20 or 22 - 24 or the third pharmaceutical composition of any one of the claims 21-24, for use as a medicament.

26. Use of the first pharmaceutical composition of claim 19, pharmaceutical combination of any one of the claims 20 or 22-24 or the third pharmaceutical composition of any one of the claims 21-24, in the manufacture of a medicament for the treatment or prophylaxis of a cancer, an infectious disease, viral infection, hypercholesterolemia, primary hyperoxaluria, haemophilia A, haemophilia B, alpha-1 antitrypsin related liver disease, acute hepatic porphyria, transthyretin-mediated amyloidosis, or an auto-immune disease.

27. *In vitro* or *ex vivo* method for transferring a molecule from outside a cell to inside said cell, preferably into the cytosol of said cell, comprising the steps of:

a) providing a cell;
b) providing the molecule for transferring from outside the cell into the cell provided in step a);
c) providing a saponin derivative according to any one of the claims 1-18;
d) contacting the cell of step a) *in vitro* or *ex vivo* with the molecule of step b) and the saponin derivative of step c), therewith establishing the transfer of the molecule from outside the cell into said cell.

28. The method of claim 27, wherein the cell is a human cell such as a T-cell, an NK-cell, a tumor cell and/or wherein the saponin derivative is the saponin derivative of any one of the claims 16-18, and/or wherein the molecule of step b) is any one of: an antibody-oligonucleotide conjugate or a receptor-ligand – oligonucleotide conjugate, wherein wherein the oligonucleotide is for example an siRNA or a BNA.